Laboratorios Farmaceuticos ROVI SA banner

Laboratorios Farmaceuticos ROVI SA
MAD:ROVI

Watchlist Manager
Laboratorios Farmaceuticos ROVI SA Logo
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Watchlist
Price: 80.35 EUR -0.62% Market Closed
Market Cap: €4.1B

Balance Sheet

Balance Sheet Decomposition
Laboratorios Farmaceuticos ROVI SA

Balance Sheet
Laboratorios Farmaceuticos ROVI SA

Rotate your device to view
Balance Sheet
Currency: EUR
Dec-2004 Dec-2005 Dec-2006 Dec-2007 Dec-2008 Dec-2009 Dec-2010 Dec-2011 Dec-2012 Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023 Dec-2024 Dec-2025
Assets
Cash & Cash Equivalents
26
12
19
17
20
36
34
50
17
15
19
29
41
41
96
67
53
99
125
25
27
98
Cash
0
0
0
0
0
0
0
0
17
15
19
29
41
41
96
67
53
99
81
25
21
98
Cash Equivalents
26
12
19
17
20
36
34
50
0
0
0
0
0
0
0
0
0
0
44
0
6
0
Short-Term Investments
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Receivables
28
28
27
37
52
60
62
72
58
59
68
61
58
52
64
92
84
160
184
143
130
178
Accounts Receivables
26
26
25
35
41
51
46
59
44
44
52
45
45
50
60
82
76
150
180
143
129
178
Other Receivables
1
3
2
2
11
9
16
13
14
16
15
16
13
2
3
10
8
10
4
0
0
0
Inventory
9
14
19
21
26
30
42
41
56
59
68
64
67
75
95
159
227
245
312
338
330
288
Other Current Assets
2
4
6
6
2
0
25
6
0
5
0
0
0
0
0
0
0
2
2
3
3
3
Total Current Assets
64
59
71
80
99
126
162
169
131
138
162
154
167
168
254
318
365
506
623
509
490
567
PP&E Net
6
11
14
22
30
33
43
46
54
60
74
82
83
89
96
132
155
182
216
254
287
331
PP&E Gross
0
0
0
22
30
33
43
46
54
60
74
82
83
89
96
132
155
182
216
254
287
331
Accumulated Depreciation
0
0
0
12
13
16
87
88
92
99
105
113
122
131
140
154
170
187
206
227
245
266
Intangible Assets
0
0
0
1
1
1
2
3
3
15
17
19
25
27
35
45
41
39
36
34
34
33
Goodwill
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
Note Receivable
0
0
0
1
1
3
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Long-Term Investments
1
1
0
0
0
0
0
0
0
0
0
0
3
2
2
2
2
2
2
1
20
19
Other Long-Term Assets
9
17
17
9
5
2
4
10
34
24
8
9
10
12
16
15
11
4
2
2
2
3
Other Assets
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
Total Assets
81
N/A
90
+11%
104
+16%
112
+8%
136
+21%
165
+21%
213
+29%
228
+7%
222
-2%
236
+6%
261
+11%
264
+1%
288
+9%
298
+4%
403
+35%
511
+27%
574
+12%
733
+28%
879
+20%
800
-9%
832
+4%
956
+15%
Liabilities
Accounts Payable
19
22
27
29
29
24
30
34
32
34
47
37
50
42
48
69
63
97
128
108
87
82
Accrued Liabilities
0
0
0
0
0
3
4
4
3
4
4
5
5
4
5
5
5
5
6
8
8
8
Short-Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
0
0
0
0
6
6
9
9
9
8
4
10
13
16
18
13
5
6
13
13
24
29
Other Current Liabilities
7
10
13
5
1
6
9
10
11
11
7
7
9
10
17
20
50
81
146
71
39
63
Total Current Liabilities
26
32
40
35
35
39
52
57
55
58
62
59
76
73
88
107
123
190
294
200
157
181
Long-Term Debt
0
0
3
10
23
26
43
41
29
23
32
33
21
27
17
72
68
67
59
52
91
93
Deferred Income Tax
4
2
2
1
1
2
2
4
3
3
2
1
2
1
1
1
1
1
1
2
0
0
Minority Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
4
10
11
Other Liabilities
10
11
18
15
9
11
12
13
8
8
7
6
6
5
10
9
9
4
3
3
3
6
Total Liabilities
40
N/A
44
+10%
62
+40%
60
-3%
67
+12%
78
+15%
109
+40%
114
+5%
96
-16%
92
-5%
103
+12%
99
-4%
104
+5%
107
+2%
115
+8%
189
+64%
201
+6%
262
+30%
359
+37%
260
-27%
260
0%
291
+12%
Equity
Common Stock
11
10
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
Retained Earnings
30
34
38
49
72
85
103
113
126
142
158
170
189
197
205
242
303
446
457
556
487
579
Additional Paid In Capital
0
1
0
0
0
0
0
0
0
0
0
0
0
0
88
88
88
88
88
88
88
88
Treasury Stock
0
0
0
0
3
1
2
2
2
1
3
8
9
8
9
10
20
66
28
108
6
5
Other Equity
0
0
0
0
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Equity
41
N/A
45
+11%
41
-9%
52
+25%
69
+32%
87
+27%
104
+19%
114
+10%
126
+11%
145
+14%
158
+10%
165
+4%
183
+11%
192
+5%
287
+50%
322
+12%
374
+16%
471
+26%
520
+10%
539
+4%
572
+6%
664
+16%
Total Liabilities & Equity
81
N/A
90
+11%
104
+16%
112
+8%
136
+21%
165
+21%
213
+29%
228
+7%
222
-2%
236
+6%
261
+11%
264
+1%
288
+9%
298
+4%
403
+35%
511
+27%
574
+12%
733
+28%
879
+20%
800
-9%
832
+4%
956
+15%
Shares Outstanding
Common Shares Outstanding
50
50
50
50
50
50
50
50
50
50
50
49
49
49
55
55
55
55
53
52
51
51
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett